Floatz logo

Irinotecan Sucrosofate

Metastatic Pancreatic Adenocarcinoma

SWOG Cancer Research NetworkSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

189 Active assets in the Metastatic Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

Irinotecan Sucrosofate is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →